🟢 AbbVie is trading 5.72% up in pre-market before scheduled Q3 results

AbbVie is trading at $307.43, up 5.72% in pre-market trading, ahead of its scheduled third-quarter report.

• AbbVie is due to report results before the market opens on October 30; it announced the timing in advance.
• Analysts expected $17.35 billion in revenue and $3.74 adjusted EPS, with attention on growth in Skyrizi and Rinvoq.
• Healthcare was up 1.32% pre-market. Available reporting showed no published results or confirmed company-specific explanation for the jump.